Losartan in diabetic nephropathy (Q35056727)

6 August 2017

1 reference

title

Losartan in diabetic nephropathy. (English)

1 reference

6 August 2017

1 reference

Christopher I Carswell

series ordinal

1

1 reference

PubMed ID

12558462

6 August 2017

Karen L Goa

series ordinal

2

1 reference

6 August 2017

1 January 2003

1 reference

6 August 2017

1 reference

6 August 2017

63

1 reference

6 August 2017

4

1 reference

6 August 2017

407-14; discussion 415-6

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200363040-00006

6 August 2017

0 references

cites work

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

1 reference

12 December 2020

Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction

1 reference

12 December 2020

The rising global burden of diabetes and its complications: estimates and projections to the year 2010.

1 reference

12 December 2020

Losartan: a review of its use, with special focus on elderly patients

1 reference

12 December 2020

Losartan, an angiotensin type 1 receptor antagonist, improves endothelial function in non-insulin-dependent diabetes.

1 reference

12 December 2020

Anaemia due to ACE inhibitors and losartan in patients with renal failure

1 reference

12 December 2020

Losartan attenuates symptomatic and hormonal responses to hypoglycemia in humans

1 reference

12 December 2020

The pharmacokinetics of losartan in renal insufficiency

1 reference

12 December 2020

Losartan, an angiotensin type I receptor antagonist, improves conduit vessel endothelial function in Type II diabetes

1 reference

12 December 2020

The losartan renal protection study--rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan)

1 reference

12 December 2020

Pharmacokinetics and blood pressure response of losartan in end-stage renal disease

1 reference

12 December 2020

Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data

1 reference

12 December 2020

Losartan reduces the costs associated with diabetic end-stage renal disease: the RENAAL study economic evaluation

1 reference

12 December 2020

Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: a systematic overview of randomized placebo-controlled trials

1 reference

12 December 2020

Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers

1 reference

12 December 2020

Effect of losartan on TGF-beta1 and urinary albumin excretion in patients with type 2 diabetes mellitus and microalbuminuria

1 reference

12 December 2020

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

1 reference

12 December 2020

Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension

1 reference

12 December 2020

Losartan titration versus diuretic combination in type 2 diabetic patients

1 reference

12 December 2020

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

1 reference

12 December 2020

Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy

1 reference

12 December 2020

Effects of angiotensin II receptor antagonist on endothelial vasomotor function and urinary albumin excretion in type 2 diabetic patients with microalbuminuria

1 reference

12 December 2020

Losartan reduces albuminuria in patients with essential hypertension. An enalapril controlled 3 months study.

1 reference

12 December 2020

Diabetic renal disease in patients with type 2 diabetes mellitus: new strategies for prevention and treatment

1 reference

12 December 2020

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group

1 reference

12 December 2020

10.2165/00003495-200363040-00006

Identifiers

DOI

1 reference

PubMed ID

12558462

Dimensions Publication ID

6 August 2017

0 references

1 reference

PubMed ID

12558462